Fusions with CD8 antigen-binding molecules for treating chronic viral infections

JP2025532960APending Publication Date: 2025-10-03ASHER BIOTHERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025518532
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-02
Filing Date
2023-09-28
Publication Date
2025-10-03

AI Technical Summary

Technical Problem

Current treatments for chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections, including co-infections, are limited by the pleiotropic effects of IL-2-based therapeutics that activate immune cell types beyond CD8+ T cells, leading to toxicity and dosage limitations.

Method used

Development of a fusion protein comprising an antibody or antigen-binding fragment that selectively binds to human CD8b/CD8ab with at least 10-fold greater affinity than CD8a/CD8aa, combined with a cytokine, chemokine, or growth factor, to target and activate CD8+ T cells without activating other immune subtypes.

Benefits of technology

The fusion protein effectively increases HBV-reactive CD8+ T cells, reduces serum HBV DNA levels, and enhances HIV-reactive CD8+ T cells, offering targeted activation with reduced toxicity and improved therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025532960000001_ABST
    Figure 2025532960000001_ABST
Patent Text Reader

Abstract

Provided herein are methods for treating a chronic viral infection (e.g., hepatitis B virus (HBV) infection and / or human immunodeficiency virus (HIV) infection), comprising administering to an individual in need thereof an effective amount of a fusion protein comprising: (a) a first portion comprising an antibody or antigen-binding fragment thereof that specifically binds to human CD8b and / or human CD8ab with an affinity that is at least 10-fold greater than its binding to human CD8a and / or human CD8aa; and (b) a second portion comprising a cytokine, chemokine, or growth factor.
Need to check novelty before this filing date? Find Prior Art